Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon F Schwartz

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Cell Cycle (Georgetown, Tex.)|June 14, 2013
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancerErik S Knudsen, Ornella Dervishaj, Celina G Kleer, et al.
Breast Cancer Research and Treatment|November 20, 2010
Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinomaKathryn C Behling, Amy Tang, Boris Freydin, et al.
The American Journal of Pathology|July 16, 2011
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironmentAgnieszka K Witkiewicz, Dayana B Rivadeneira, Adam Ertel, et al.
Cancer|February 15, 2011
Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alonePhoebe Holmes, Joshua Lloyd, Inna Chervoneva, et al.
Journal of the National Cancer Institute|December 1, 2012
Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progressionErik S Knudsen, Thomas F Pajak, Maria Qeenan, et al.
Cancer|May 26, 2004
The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery aloneDennis B Cornfield, Juan P Palazzo, Gordon F Schwartz, et al.
The Breast Journal|April 26, 2013
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlationJulianne R Biroschak, Gordon F Schwartz, Juan P Palazzo, et al.
Cancer Biology & Therapy|June 25, 2010
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrenceAgnieszka K Witkiewicz, Boris Freydin, Inna Chervoneva, et al.
Cancer|March 7, 2012
Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotypingGordon F Schwartz, Jorge Reis-Fihlo, Lajos Pusztai, et al.
Cancer Biology & Therapy|June 9, 2009
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancerAgnieszka K Witkiewicz, Abhijit Dasgupta, Katherine H Nguyen, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Cell Cycle (Georgetown, Tex.)|June 14, 2013
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancerErik S Knudsen, Ornella Dervishaj, Celina G Kleer, et al.
Breast Cancer Research and Treatment|November 20, 2010
Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinomaKathryn C Behling, Amy Tang, Boris Freydin, et al.
The American Journal of Pathology|July 16, 2011
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironmentAgnieszka K Witkiewicz, Dayana B Rivadeneira, Adam Ertel, et al.
Cancer|February 15, 2011
Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alonePhoebe Holmes, Joshua Lloyd, Inna Chervoneva, et al.
Journal of the National Cancer Institute|December 1, 2012
Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progressionErik S Knudsen, Thomas F Pajak, Maria Qeenan, et al.
Cancer|May 26, 2004
The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery aloneDennis B Cornfield, Juan P Palazzo, Gordon F Schwartz, et al.
The Breast Journal|April 26, 2013
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlationJulianne R Biroschak, Gordon F Schwartz, Juan P Palazzo, et al.
Cancer Biology & Therapy|June 25, 2010
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrenceAgnieszka K Witkiewicz, Boris Freydin, Inna Chervoneva, et al.
Cancer|March 7, 2012
Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotypingGordon F Schwartz, Jorge Reis-Fihlo, Lajos Pusztai, et al.
Cancer Biology & Therapy|June 9, 2009
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancerAgnieszka K Witkiewicz, Abhijit Dasgupta, Katherine H Nguyen, et al.
Pageof 4